Cargando…
All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study
Statins have been advocated as a potential treatment for coronavirus disease-2019 (COVID-19) due to its pleotropic properties. The aim of the study was to elucidate the association between antecedent statin exposure and 30-day all-cause mortality, intensive care unit (ICU) admission and hypoxic resp...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505477/ https://www.ncbi.nlm.nih.gov/pubmed/34637080 http://dx.doi.org/10.1007/s11739-021-02848-z |
_version_ | 1784581541409587200 |
---|---|
author | El-Solh, Ali A. Lawson, Yolanda El-Solh, Daniel A. |
author_facet | El-Solh, Ali A. Lawson, Yolanda El-Solh, Daniel A. |
author_sort | El-Solh, Ali A. |
collection | PubMed |
description | Statins have been advocated as a potential treatment for coronavirus disease-2019 (COVID-19) due to its pleotropic properties. The aim of the study was to elucidate the association between antecedent statin exposure and 30-day all-cause mortality, intensive care unit (ICU) admission and hypoxic respiratory failure requiring mechanical ventilation in patients diagnosed with COVID-19. Observational cohort study derived from the VA Corporate Data Warehouse of all veterans tested positive for COVID-19 between January 1st and May 31st, 2020. Antecedent use of statins was defined as a redeemed drug prescription in the 6 months prior to COVID-19 diagnosis. Propensity-matched mixed-effects logistic regression was performed, stratified by statin use. The study population comprised 14,268 patients with COVID-19 (median age 66 years (25th–75th percentile, 53–74), 90.7% men), of whom 7,168 were receiving a prescription for statins. Patients with statin exposure had a greater prevalence of comorbidities and a higher risk of mortality (Odd ratio [OR] 1.52; 95% confidence interval [CI] 1.37–1.68). After adjusting for covariates, statin exposure was not associated with a decreased mortality in the overall cohort by either Cox proportional hazards stratified model (HR 0.99; 95% CI 0.88–1.12) or propensity matching (HR .86; 95% CI 0.74–1.01). Similarly, there was no demonstrated advantage of statins in reducing the risk of ICU admission (HR 0.92; 95% CI 0.74–1.31) or hypoxic respiratory failure requiring mechanical ventilation (HR 1.02; 95% CI 0.81–1.29). Antecedent statin exposure in patients with COVID-19 was not associated with a decreased risk of 30-day all-cause mortality or need for mechanical ventilation. |
format | Online Article Text |
id | pubmed-8505477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-85054772021-10-12 All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study El-Solh, Ali A. Lawson, Yolanda El-Solh, Daniel A. Intern Emerg Med Im - Original Statins have been advocated as a potential treatment for coronavirus disease-2019 (COVID-19) due to its pleotropic properties. The aim of the study was to elucidate the association between antecedent statin exposure and 30-day all-cause mortality, intensive care unit (ICU) admission and hypoxic respiratory failure requiring mechanical ventilation in patients diagnosed with COVID-19. Observational cohort study derived from the VA Corporate Data Warehouse of all veterans tested positive for COVID-19 between January 1st and May 31st, 2020. Antecedent use of statins was defined as a redeemed drug prescription in the 6 months prior to COVID-19 diagnosis. Propensity-matched mixed-effects logistic regression was performed, stratified by statin use. The study population comprised 14,268 patients with COVID-19 (median age 66 years (25th–75th percentile, 53–74), 90.7% men), of whom 7,168 were receiving a prescription for statins. Patients with statin exposure had a greater prevalence of comorbidities and a higher risk of mortality (Odd ratio [OR] 1.52; 95% confidence interval [CI] 1.37–1.68). After adjusting for covariates, statin exposure was not associated with a decreased mortality in the overall cohort by either Cox proportional hazards stratified model (HR 0.99; 95% CI 0.88–1.12) or propensity matching (HR .86; 95% CI 0.74–1.01). Similarly, there was no demonstrated advantage of statins in reducing the risk of ICU admission (HR 0.92; 95% CI 0.74–1.31) or hypoxic respiratory failure requiring mechanical ventilation (HR 1.02; 95% CI 0.81–1.29). Antecedent statin exposure in patients with COVID-19 was not associated with a decreased risk of 30-day all-cause mortality or need for mechanical ventilation. Springer International Publishing 2021-10-12 2022 /pmc/articles/PMC8505477/ /pubmed/34637080 http://dx.doi.org/10.1007/s11739-021-02848-z Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Im - Original El-Solh, Ali A. Lawson, Yolanda El-Solh, Daniel A. All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study |
title | All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study |
title_full | All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study |
title_fullStr | All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study |
title_full_unstemmed | All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study |
title_short | All-cause mortality in COVID-19 patients receiving statin therapy: analysis of veterans affairs database cohort study |
title_sort | all-cause mortality in covid-19 patients receiving statin therapy: analysis of veterans affairs database cohort study |
topic | Im - Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505477/ https://www.ncbi.nlm.nih.gov/pubmed/34637080 http://dx.doi.org/10.1007/s11739-021-02848-z |
work_keys_str_mv | AT elsolhalia allcausemortalityincovid19patientsreceivingstatintherapyanalysisofveteransaffairsdatabasecohortstudy AT lawsonyolanda allcausemortalityincovid19patientsreceivingstatintherapyanalysisofveteransaffairsdatabasecohortstudy AT elsolhdaniela allcausemortalityincovid19patientsreceivingstatintherapyanalysisofveteransaffairsdatabasecohortstudy |